File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The effect of N-acetylcysteine on cardiac contractility to dobutamine in rats with streptozotocin-induced diabetes

TitleThe effect of N-acetylcysteine on cardiac contractility to dobutamine in rats with streptozotocin-induced diabetes
Authors
KeywordsAntioxidant
Cardiac contractility
Inducible nitric oxide synthase
Isoprostane
Nitrotyrosine
Issue Date2005
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar
Citation
European Journal Of Pharmacology, 2005, v. 519 n. 1-2, p. 118-126 How to Cite?
AbstractWe examined if myocardial depression at the acute phase of diabetes (3 weeks after injection of streptozotocin, 60 mg/kg i.v.) is due to activation of inducible nitric oxide synthase and production of peroxynitrite, and if treatment with N-acetylcysteine (1.2 g/day/kg for 3 weeks, antioxidant) improves cardiac function. Four groups of rats were used: control, N-acetylcysteine- treated control, diabetic and N-acetylcysteine-treated diabetic. Pentobarbital-anaesthetized diabetic rats, relative to the controls, had reduced left ventricular contractility to dobutamine (1-57 μg/min/kg). The diabetic rats also had increased myocardial levels of thiobarbituric acid reactive substances, immunostaining of inducible nitric oxide synthase and nitrotyrosine, and similar baseline 15-F2t-isoprostane. N-acetylcysteine did not affect responses in the control rats; but increased cardiac contractility to dobutamine, reduced myocardial immunostaining of inducible nitric oxide synthase and nitrotyrosine and level of 15-F2t-isoprostane, and increased cardiac contractility to dobutamine in the diabetic rats. Antioxidant supplementation in diabetes reduces oxidative stress and improves cardiac function. © 2005 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/147221
ISSN
2023 Impact Factor: 4.2
2023 SCImago Journal Rankings: 1.055
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheng, Xen_US
dc.contributor.authorXia, Zen_US
dc.contributor.authorLeo, JMen_US
dc.contributor.authorPang, CCYen_US
dc.date.accessioned2012-05-29T06:00:52Z-
dc.date.available2012-05-29T06:00:52Z-
dc.date.issued2005en_US
dc.identifier.citationEuropean Journal Of Pharmacology, 2005, v. 519 n. 1-2, p. 118-126en_US
dc.identifier.issn0014-2999en_US
dc.identifier.urihttp://hdl.handle.net/10722/147221-
dc.description.abstractWe examined if myocardial depression at the acute phase of diabetes (3 weeks after injection of streptozotocin, 60 mg/kg i.v.) is due to activation of inducible nitric oxide synthase and production of peroxynitrite, and if treatment with N-acetylcysteine (1.2 g/day/kg for 3 weeks, antioxidant) improves cardiac function. Four groups of rats were used: control, N-acetylcysteine- treated control, diabetic and N-acetylcysteine-treated diabetic. Pentobarbital-anaesthetized diabetic rats, relative to the controls, had reduced left ventricular contractility to dobutamine (1-57 μg/min/kg). The diabetic rats also had increased myocardial levels of thiobarbituric acid reactive substances, immunostaining of inducible nitric oxide synthase and nitrotyrosine, and similar baseline 15-F2t-isoprostane. N-acetylcysteine did not affect responses in the control rats; but increased cardiac contractility to dobutamine, reduced myocardial immunostaining of inducible nitric oxide synthase and nitrotyrosine and level of 15-F2t-isoprostane, and increased cardiac contractility to dobutamine in the diabetic rats. Antioxidant supplementation in diabetes reduces oxidative stress and improves cardiac function. © 2005 Elsevier B.V. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejpharen_US
dc.relation.ispartofEuropean Journal of Pharmacologyen_US
dc.subjectAntioxidant-
dc.subjectCardiac contractility-
dc.subjectInducible nitric oxide synthase-
dc.subjectIsoprostane-
dc.subjectNitrotyrosine-
dc.subject.meshAcetylcysteine - Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntioxidants - Metabolismen_US
dc.subject.meshBlood Glucose - Metabolismen_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshDiabetes Mellitus, Experimental - Blood - Physiopathologyen_US
dc.subject.meshDinoprost - Analogs & Derivatives - Metabolismen_US
dc.subject.meshDobutamine - Pharmacologyen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshHeart Rate - Drug Effectsen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshMaleen_US
dc.subject.meshMyocardial Contraction - Drug Effectsen_US
dc.subject.meshMyocardium - Metabolismen_US
dc.subject.meshNitric Oxide Synthase - Analysisen_US
dc.subject.meshNitric Oxide Synthase Type Iien_US
dc.subject.meshNitric Oxide Synthase Type Iiien_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Wistaren_US
dc.subject.meshThiobarbituric Acid Reactive Substances - Metabolismen_US
dc.subject.meshTyrosine - Analogs & Derivatives - Analysisen_US
dc.titleThe effect of N-acetylcysteine on cardiac contractility to dobutamine in rats with streptozotocin-induced diabetesen_US
dc.typeArticleen_US
dc.identifier.emailXia, Z:zyxia@hkucc.hku.hken_US
dc.identifier.authorityXia, Z=rp00532en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ejphar.2005.06.037en_US
dc.identifier.pmid16111676-
dc.identifier.scopuseid_2-s2.0-27744485267en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-27744485267&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume519en_US
dc.identifier.issue1-2en_US
dc.identifier.spage118en_US
dc.identifier.epage126en_US
dc.identifier.isiWOS:000231847100018-
dc.publisher.placeNetherlandsen_US
dc.identifier.issnl0014-2999-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats